Bioentrepreneur | Published:

Biocon's target factory

Nature Biotechnology volume 36, pages 791797 (2018) | Download Citation

South Korea's 8-year effort to create an integrated platform for novel target and lead development provides an academic drug discovery model for other emerging economies.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Organisation for Economic Co-operation and Development. OECD Education at a Glance 2014 (OECD Publishing, 2014).

  2. 2.

    et al. Nat. Commun. 8, 15090 (2017).

  3. 3.

    et al. Cancer Res. 76, 1044–1054 (2016).

  4. 4.

    et al. J. Clin. Invest. 125, 4042–4052 (2015).

  5. 5.

    et al. Nano Lett. 15, 2938–2944 (2015).

  6. 6.

    et al. Science 354, 623–626 (2016).

  7. 7.

    et al. Nat. Commun. 6, 6402 (2015).

  8. 8.

    , , & Nature 494, 121–124 (2013).

  9. 9.

    et al. Acta Crystallogr. D Biol. Crystallogr. 69, 2136–2145 (2013).

  10. 10.

    , & FASEB J. 12, 1599–1609 (1998).

  11. 11.

    et al. Science 316, 1759–1761 (2007).

  12. 12.

    et al. Proc. Natl. Acad. Sci. USA 111, E5508–E5517 (2014).

  13. 13.

    et al. Circulation 136, A24036 (2017).

  14. 14.

    et al. Proc. Natl. Acad. Sci. USA 109, E640–E647 (2012).

  15. 15.

    et al. Nat. Microbiol. 2, 16191 (2016).

  16. 16.

    et al. J. Cell Biol. 216, 2201–2216 (2017).

  17. 17.

    et al. J. Biol. Chem. 276, 6030–6036 (2001).

  18. 18.

    et al. Cell 149, 410–424 (2012).

  19. 19.

    et al. FASEB J. 26, 4142–4159 (2012).

  20. 20.

    et al. ACS Pharmacol. Transl. Sci. (2018).

  21. 21.

    , & Nat. Rev. Cancer 11, 708–718 (2011).

  22. 22.

    et al. PLoS Genet. 7, e1001351 (2011).

  23. 23.

    et al. J. Mol. Cell Biol. 4, 164–173 (2012).

  24. 24.

    et al. Biochem. J. 454, 411–416 (2013).

  25. 25.

    , & Trends Biochem. Sci. 30, 569–574 (2005).

  26. 26.

    et al. J. Mol. Biol. 423, 475–481 (2012).

  27. 27.

    et al. Nat. Commun. 8, 732 (2017).

  28. 28.

    et al. Nat. Chem. Biol. 10, 29–34 (2014).

  29. 29.

    et al. Exp. Mol. Med. 50, e424 (2018).

  30. 30.

    et al. Nat. Immunol. 17, 1252–1262 (2016).

  31. 31.

    et al. Nat. Mater. 10, 747–752 (2011).

  32. 32.

    , & Angew. Chem. Int. Ed. Engl. 51, 5447–5451 (2012).

  33. 33.

    et al. Adv. Mater. 24, 5924–5929 (2012).

Download references

Acknowledgements

This work was supported by a Global Frontier Project grant (NRF-M3A6A4-2010-0029785).

Author information

Affiliations

  1. Thomas X. Neenan, Robert E. Burrier and Sunghoon Kim are at the Medicinal Bioconvergence Research Center (Biocon), Seoul, South Korea

    • Thomas X Neenan
    • , Robert E Burrier
    •  & Sunghoon Kim
  2. Sunghoon Kim is in the Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology and College of Pharmacy, Seoul National University, Seoul, South Korea.

    • Sunghoon Kim

Authors

  1. Search for Thomas X Neenan in:

  2. Search for Robert E Burrier in:

  3. Search for Sunghoon Kim in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Sunghoon Kim.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.4242

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing